Guyer William sold $1.8M of CORT
Guyer William (Chief Development Officer) sold 16,300 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $113.43 ($113.18–$114.04, $1.85M total) across 2 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is a disclosed change in insider ownership, but the article provides no new information about Corcept’s business, pipeline, or financial outlook.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 framing reduces the likelihood of a fundamental repricing catalyst.
What to watch
The filing does not indicate whether the officer’s remaining holdings or future scheduled sales change, and it provides no link to any new Corcept development.
Background
SEC Form 4 reports an insider open-market sale by Corcept Therapeutics CDO Guyer William, executed under a pre-arranged 10b5-1 plan.
Ticker impact
Corcept Therapeutics insider sale: CDO Guyer William sold 16,300 shares on 2026-08-10 at about $113.18 to $114.04 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-only and typically fades as 10b5-1 sales are pre-planned.
The disclosure is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific fundamentals or guidance.
Market effects
Minimal; single-company insider sale does not change sector fundamentals.
None indicated.
None indicated.
Counterpoint
10b5-1 sales can be purely administrative liquidity events, so the market may overreact if it treats it as a bearish signal.
Key entities
- issuerCorcept Therapeutics Inc
Company whose insider transaction is disclosed on SEC Form 4.
- insiderGuyer William
Chief Development Officer who sold 16,300 shares on 2026-08-10 under a 10b5-1 plan.
